Capital World Investors Increases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Capital World Investors boosted its stake in Jazz by 0.4% in Q3 to 2,554,867 shares (a 4.20% position) valued at about $336.7 million.
• Insiders have been net sellers: 68,015 shares were sold in the last 90 days (≈$13.04M), including EVP Neena M. Patil’s 55,600-share sale, leaving corporate insiders with roughly 4.30% ownership.
• Operational and analyst outlook: Jazz beat the quarter with $6.64 EPS and $1.20B revenue (revenue +8.1% YoY), and analysts are broadly bullish with a consensus target around $214.38.

Capital World Investors increased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,554,867 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,345 shares during the quarter. Capital World Investors owned 4.20% of Jazz Pharmaceuticals worth $336,731,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Dimensional Fund Advisors LP boosted its stake in shares of Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after acquiring an additional 298,815 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $2,697,000. Kennedy Capital Management LLC acquired a new position in Jazz Pharmaceuticals during the second quarter worth $1,100,000. Wedge Capital Management L L P NC acquired a new position in Jazz Pharmaceuticals during the third quarter worth $27,834,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter worth $605,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Patricia Carr sold 1,287 shares of the firm's stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the completion of the sale, the executive vice president directly owned 56,862 shares of the company's stock, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 68,015 shares of company stock valued at $13,037,486. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 0.3%

JAZZ opened at $185.43 on Thursday. The firm has a market cap of $11.42 billion, a P/E ratio of -31.06, a PEG ratio of 0.34 and a beta of 0.22. The business's fifty day simple moving average is $172.02 and its 200 day simple moving average is $155.43. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm's revenue for the quarter was up 8.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.51 EPS. As a group, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on JAZZ shares. Truist Financial raised their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Monday, January 12th. Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an "outperform" rating in a report on Tuesday, November 18th. Bank of America lifted their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Barclays reaffirmed an "overweight" rating and issued a $224.00 price target on shares of Jazz Pharmaceuticals in a report on Monday. Finally, Piper Sandler reiterated an "overweight" rating and issued a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $214.38.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.